Email this article PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY
- Authors: Kharkevich G.Y.1, Demidov L.V.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 9, No 2 (2013)
- Pages: 26-34
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.06.2013
- URL: https://oncourology.abvpress.ru/oncur/article/view/91
- DOI: https://doi.org/10.17650/1726-9776-2013-9-2-26-34
- ID: 91
Cite item
Full Text
Abstract
The paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.
About the authors
G. Yu. Kharkevich
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: gkharkevich@mail.ru
Russian Federation
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: gkharkevich@mail.ru
Russian Federation
References
Supplementary files
